Recent 8-K filings for NWBO

• April 7, 2026, 7:59 PM ET M&A materiality 0.65 neutral item 2.01item 9.01 ◈ M&A Transactions

  Northwest Biotherapeutics completes acquisition of UK CDMO Advent BioServices for ~$1.9M plus ~$8.3M payables

  Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.

• January 15, 2026, 6:59 PM ET litigation materiality 0.55 positive item 8.01

  NWBO settles 2020 option litigation; insurer pays $2.25M, 17% options cancelled

  Settlement agreement entered Dec 12, 2025 for litigation over 2020 option awards.

• January 2, 2026, 6:59 PM ET other material materiality 0.60 neutral item 5.07item 5.03item 9.01 ◈ Governance Changes

  NWBO shareholders OK share increase to 2.6B, elect Pat Sarma

  Authorized common shares increased from 1.7B to 2.6B; 89.65% of votes cast in favor.

• November 20, 2025, 6:59 PM ET debt materiality 0.70 neutral item 1.01item 2.03 ◈ Debt Financings

  NWBO enters $5M convertible note with Yorkville for Sawston facility

  Promissory note of $5M with YA II PN, Ltd. (Yorkville) for 12 months, no payments due until maturity.

• October 31, 2025, 7:59 PM ET debt materiality 0.55 neutral item 1.01item 2.03 ◈ Debt Financings

  NW Biotherapeutics enters $5.5M loan agreement with Streeterville Capital

  Loan amount $5,505,000; maturity 22 months; interest 8% p.a.; 10% original issue discount.

• October 30, 2025, 7:59 PM ET M&A materiality 0.55 positive item 1.01

  NWBO closes Advent BioServices acquisition; pays £1.4M + AP over 2 years; 19M securities revert

  Acquisition of Advent BioServices closed; Advent becomes wholly owned subsidiary.

• October 24, 2025, 7:59 PM ET other material materiality 0.05 neutral item 8.01

  NWBO files new Form S-3 shelf registration to replace expiring registration on Oct 25, 2025

  Filed new S-3 shelf registration on October 23, 2025, effective for three years.

• October 14, 2025, 7:59 PM ET litigation materiality 0.60 neutral item 8.01

  Northwest Biotherapeutics settles shareholder litigation over 2020 options; insurers to pay $2.25M

  Settlement resolves Delaware Chancery litigation over 2020 option awards to management and directors.

• December 26, 2024, 6:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 9.01

  Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility

  Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.

• November 1, 2024, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03

  Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity

  Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.

• August 2, 2024, 7:59 PM ET other materiality 0.40 neutral item 7.01

  NW Bio investigates social media rumors; MHRA MAA review continues

  Company probing rumors linked to parties in federal NY lawsuit; coinciding with stock market developments.

• July 3, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  NWBO annual meeting re-elects directors, ratifies auditor and option awards, approves exec comp

  Re-elected Dr. Alton L. Boynton (94.04% for) and Ambassador J. Cofer Black (93.01% for) as Class I directors for three-year terms.

• June 4, 2024, 7:59 PM ET other material materiality 0.40 neutral item 1.01

  Northwest Biotherapeutics sells 8.125M shares at $0.40 to SIO Capital for $3.25M

  SPA signed June 4, 2024; closing expected June 5, 2024.

• May 2, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03 ◈ Debt Financings◈ Material Agreements

  Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital

  Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.55 · Most common event debt

2 positive 0 negative 12 neutral

source · NWBO on sec.gov